The development of a Psoriasis Rapid Access Clinic (P-RAC)

The development of a Rapid Access Clinic for patients with Psoriasis (P-RAC)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15867502

Enrollment

Registered

2018-12-11

Start date

2018-11-26

Completion date

Unknown

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Skin and Connective Tissue Diseases Psoriasis

Interventions

At baseline, patients will have a full assessment of their psoriasis by a specialist dermatologist, which will include a physical examination, definitive diagnosis, severity scoring, and screening for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 16 years or older 2. Currently living in Salford 3. Registered with a Salford GP 4. Developed psoriasis over the past 2 years or prospective new diagnoses of psoriasis occurring in Salford during the course of this pilot study

Exclusion criteria

Exclusion criteria: 1. Psychiatric or other disorder that may impact on informed consent 2. Currently under the active care of hospital dermatology services for psoriasis 3. On systemic therapy or ultraviolet (UV) therapy for psoriasis

Design outcomes

Primary

Measure	Time frame
Feasibility and practicality of a Psoriasis Rapid Access Clinic for newly diagnosed patients with psoriasis, assessed using: 1. Recruitment rate recorded as the number of eligible participants seen at the clinic, and the continuation rate of patients to follow-ups at 4 and 24 weeks 2. The cost-effectiveness of the clinic determined by the set up costs, running costs and the longer-term health economic gains e.g. improvement in work productivity (Work Productivity and Activity Impairment questionnaire at baseline and 24 weeks) 3. Does a patient’s understanding of psoriasis improve with the P-RAC intervention? (Determined by Understanding of psoriasis and treatment questionnaires at all time points) 4. Does the intervention lead to improvements in a patient’s physical and emotional well-being? (Determined by changes from baseline to week 4 and week 24 follow-up measurements in: weight and waist circumference, anxiety and depression (using the Hospital Anxiety and Depression Scale), Generic Health Utility Index (Patient Baseline EuroQol – EQ5D), Psoriasis extent and severity (measured by physical examination (using measures such as Simplified Psoriasis Index, Physician Global Assessment and Psoriasis Area and Severity Index) and patient answered Dermatology Life Quality Index), as well assessments of smoking, alcohol consumption and exercise.	—

Measure

Time frame

Feasibility and practicality of a Psoriasis Rapid Access Clinic for newly diagnosed patients with psoriasis, assessed using: 1. Recruitment rate recorded as the number of eligible participants seen at the clinic, and the continuation rate of patients to follow-ups at 4 and 24 weeks 2. The cost-effectiveness of the clinic determined by the set up costs, running costs and the longer-term health economic gains e.g. improvement in work productivity (Work Productivity and Activity Impairment questionnaire at baseline and 24 weeks) 3. Does a patient’s understanding of psoriasis improve with the P-RAC intervention? (Determined by Understanding of psoriasis and treatment questionnaires at all time points) 4. Does the intervention lead to improvements in a patient’s physical and emotional well-being? (Determined by changes from baseline to week 4 and week 24 follow-up measurements in: weight and waist circumference, anxiety and depression (using the Hospital Anxiety and Depression Scale), Generic Health Utility Index (Patient Baseline EuroQol – EQ5D), Psoriasis extent and severity (measured by physical examination (using measures such as Simplified Psoriasis Index, Physician Global Assessment and Psoriasis Area and Severity Index) and patient answered Dermatology Life Quality Index), as well assessments of smoking, alcohol consumption and exercise.

—

Secondary

Measure	Time frame
1. The pathophysiology and treatment of early psoriatic disease amongst this patient cohort, assessed by collecting blood samples at baseline which will be processed and stored for future genomic and proteomic research to learn more about the cause of psoriasis and better inform treatment options in the future 2. The prevalence of comorbidities including psoriatic arthritis (using Psoriasis epidemiology Screening Tool and physical examination at baseline) , depression and anxiety (using the Hospital Anxiety and Depression Scale questionnaire as well as qualitative data at all time points), and cardiovascular disease risk factors (baseline only, using QRISK3).	—

Measure

Time frame

1. The pathophysiology and treatment of early psoriatic disease amongst this patient cohort, assessed by collecting blood samples at baseline which will be processed and stored for future genomic and proteomic research to learn more about the cause of psoriasis and better inform treatment options in the future 2. The prevalence of comorbidities including psoriatic arthritis (using Psoriasis epidemiology Screening Tool and physical examination at baseline) , depression and anxiety (using the Hospital Anxiety and Depression Scale questionnaire as well as qualitative data at all time points), and cardiovascular disease risk factors (baseline only, using QRISK3).

—

Countries

England, United Kingdom

Contacts

Public ContactSoney Dharmaprasad

PRAC@srft.nhs.uk+44 (0)161 206 0891

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026